Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
In mid-2025, President Trump reissued an executive order on Most Favored Nation (MFN) drug pricing, which ties U.S. prices for selected drugs to the lowest price paid in comparable developed countries. By November 2025, CMS introduced two mandatory models (GLOBE and GUARD) for participating drugmakers, along with an optional model that makes MFN pricing available to state Medicaid programs via manufacturer rebates.
As the GLOBE model is slated to go into effect on January 1, 2027, health plans and PBMs now…
Nearly four years after the IRA became law, its most closely watched provision is no longer theoretical. CMS-negotiated pricing for the first round of selected high-expenditure Medicare Part D drugs took effect in January 2026. These negotiated prices, referred to as Maximum Fair Prices (MFPs), reflect reductions from 2023 list prices ranging from 38% to 79%.
Payers say they were ready. In MMIT's Q2 2026 Indices IRA survey, payers representing 74% of Medicare lives reported being well prepared for the January…
More than 20 years ago, GLP-1 receptor agonists entered the market as type 2 diabetes therapies, building steady commercial success on the strength of durable A1C reduction, once-weekly dosing, and a low risk of hypoglycemia. The first such therapy was exenatide, introduced in 2005, followed by liraglutide (2010), dulaglutide (2014), and semaglutide (2017).
But for all that momentum, the class had not yet reached blockbuster status. That trajectory changed in 2021 with the approval of Wegovy for chronic weight management, marking…
For years, the pharmaceutical industry has measured R&D productivity at the wrong moment in time: FDA approval. However, approval is only one checkpoint. The harder questions come afterwards: Will payers cover this drug? Will patients start treatment? Will the investment ultimately pay off?
A new index from Norstella is reframing how the industry answers those questions. The Pipeline-to-Patient Productivity Index (P3i) is the first benchmarking tool that follows a molecule across its entire journey: from early disclosure through clinical development, into…
Market access teams spend a lot of time preparing for payer meetings, but they rarely know how well those meetings went. To answer that need, MMIT’s Message Monitor has been capturing unaided, immediate payer feedback on pharma meetings for the past 15 years, providing clients with qualitative and quantitative data.
Now, with the platform's new self-service interface and Ella AI querying tool, teams can explore the entire Message Monitor archive directly, asking the kinds of strategy questions that used to require…
Pharma companies are deploying AI tools across a broad range of market access functions, from payer account strategy to contracting and beyond. According to our 2026 State of Patient Access research, 65% say that AI and RWD are ‘very important’ or ‘mission-critical’ to their access models today.
We sat down with two MMIT experts, Liz Rolla and Carolyn Zele, for a candid conversation about what AI can actually do for market access teams, how it's changing the role of analysts, and…
Biosimilar adoption and vertical integration used to be separate challenges for manufacturers — one focused on formulary competition, the other on navigating payer consolidation. New Q2 2026 MMIT Indices research suggests they've merged into a single prevailing pressure.
As more payers fold PBMs, specialty pharmacies, and even physician practices into their own operations, the same consolidated entities now setting formulary strategy are also the ones deciding a biosimilar's fate. Manufacturers of biosimilars are no longer just competing against reference products. Instead,…
For years, immunology has ranked as one of the top therapeutic areas by value, with year-over-year growth driven by blockbuster biologics for conditions like rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). Now, a wave of therapies with novel mechanisms of action (MoAs) is expanding the immunology conditions that can be treated, even as biosimilars and Medicare price negotiation compress the value of legacy brands.
The top 20 immunology drugs generated roughly $81 billion in 2024, growing at nearly 9.4%…
Pharma manufacturers invest significant time and money developing resources for payers, from budget impact models to PIE packages and NCCN summaries. But are those resources hitting the mark?
New Q1 2026 MMIT Indices research, surveying commercial payers representing more than 126 million covered lives and Medicare plans representing 50 million lives, offers a few insights. The findings reveal not just what payers say they want, but where most manufacturer-provided materials still fall short.
On the clinical side, payers want detailed efficacy…
After years of record growth driven by subsidized premiums, enrollment in Affordable Care Act (ACA) exchange plans plummeted this year from its all-time high of 24.3 million members in 2025. Enrollment in Medicaid and commercial group risk plans is on the decline, while Medicare enrollment is more static; meanwhile, enrollment in commercial ASO/self-funded plans is on the upswing.
What do these shifts mean for providers, manufacturers, payers and health IT vendors? Let’s take a look at the data from MMIT’s Directory of…